Curaleaf Holdings (CURLF) Liabilities and Shareholders Equity (2019 - 2025)
Curaleaf Holdings (CURLF) recorded quarterly Liabilities and Shareholders Equity of $2.8 billion in Q4 2025, down 3.54% quarter-over-quarter from $2.9 billion in Q4 2024, and down 3.54% on a YoY basis from $2.9 billion in Q4 2024.
Curaleaf Holdings (CURLF) Liabilities and Shareholders Equity (2019 - 2025) Analysis & Trends
Curaleaf Holdings' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $2.8 billion for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 3.54% year-over-year to $2.8 billion; the TTM figure through Mar 2026 stood at $2.8 billion (down 68.76% YoY), while the FY2025 annual figure was $2.8 billion, down 3.54% from the prior year.
- Liabilities and Shareholders Equity was $2.8 billion for Q4 2025 at Curaleaf Holdings, down from $2.9 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.5 billion in Q1 2022 to a low of $2.7 billion in Q1 2021.
- Historically, Liabilities and Shareholders Equity has averaged $3.1 billion across 5 years, with a median of $3.1 billion in 2021.
- The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity surged 34.57% in 2021, then decreased 6.67% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $3.1 billion in 2021, then increased by 14.31% to $3.5 billion in 2022, then fell by 12.76% to $3.1 billion in 2023, then decreased by 4.74% to $2.9 billion in 2024, then dropped by 3.54% to $2.8 billion in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $2.8 billion (Q4 2025), $2.9 billion (Q4 2024), and $3.1 billion (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 2.27 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.35 Bn |
| 10 | Curaleaf Holdings | - | - | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.85 Bn |
| Dec 31, 2024 | 2.95 Bn |
| Sep 30, 2024 | 3.07 Bn |
| Jun 30, 2024 | 3.08 Bn |
| Dec 31, 2023 | 3.10 Bn |
| Sep 30, 2023 | 3.23 Bn |
| Jun 30, 2023 | 3.30 Bn |
| Mar 31, 2022 | 3.55 Bn |
| Dec 31, 2021 | 3.11 Bn |
| Sep 30, 2021 | 3.17 Bn |
| Jun 30, 2021 | 3.15 Bn |
| Mar 31, 2021 | 2.68 Bn |
| Dec 31, 2020 | 2.37 Bn |
| Sep 30, 2020 | 2.36 Bn |
| Dec 31, 2019 | 736.93 Mn |